TLSA
Tiziana Life Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$1.01
−3.81%Oct 16, 2026, 11:00 UTC
Tiziana Life Sciences Ltd announced that the last patient began dosing in its Phase 2 trial of intranasal foralumab for early/mild Alzheimer's disease.
Sep 28, 2026, 13:32 UTC
Tiziana Life Sciences dosed the first three participants with intranasal foralumab in a Phase 2a trial in people with amyotrophic lateral sclerosis (ALS).
Source:Sep 22, 2026, 23:59 UTC
KAIMRC announced research collaborations with Olink in proteomics, Tiziana Life Sciences in immunomodulation and neuroimmunology, and Japan's Chiyoda Corporation on plant-based peptide production for cancer treatment.
Source:Sep 21, 2026, 13:42 UTC
Tiziana Life Sciences completed the final patient visit in its Phase 2a INFORM-MS trial of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis, with 48 patients enrolled across three cohorts at U.S. sites.
Source:Sep 17, 2026, 13:30 UTC
Tiziana Life Sciences signed a memorandum of understanding with King Abdullah International Medical Research Center and partners to support a planned clinical trial of intranasal foralumab combined with anti-CD20 therapy in relapsing-remitting multiple sclerosis patients.
Aug 24, 2026, 12:49 UTC
Tiziana Life Sciences announced it will present Phase 2a BANYAN trial data for intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday.
Source:Jul 31, 2026, 17:32 UTC
Tiziana Life Sciences announced promising quantitative PET imaging results from the third patient in its Phase 2 clinical trial for a rare neurodegenerative condition, showing reduced neuroinflammation.
Source:Jun 25, 2026, 13:06 UTC
Tiziana Life Sciences dosed the last patient in its Phase 2a clinical trial of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis.
Source: